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Iridium-catalysed ortho-H/D and -H/T Exchange under Basic 
Conditions: C-H Activation of Unprotected Tetrazoles 
William J. Kerr,*a David M. Lindsay,a Marc Reid,a Jens Atzrodt,b Volker Derdau,b Patrick Rojahn,b 
and Remo Weckb
The first examples of selective ortho-directed C-H activation with 
unprotected 2-aryltetrazoles are described. A new base-assisted 
protocol for iridium (I) hydrogen isotope exchange catalysis allows 
access to ortho-deuterated and tritiated tetrazoles, including the 
tetrazole-containing pharmaceutical, Valsartan. Preliminary 
mechanistic studies are also presented. 
 Compounds labelled with hydrogen isotopes (deuterium or 
tritium) have widespread applications in synthetic, 
mechanistic, and metabolic studies.1 ?4 Recently, we5 ?7 and 
others8 ?11 have focused on metal-catalysed C-H 
functionalisation12 ?17 methods towards efficient installation of 
the desired isotopic label via hydrogen isotope exchange (HIE). 
Of related interest, tetrazoles represent an important class of 
azacyclic functionality in drug design, and have been employed 
with appreciable success within an array of therapeutic agents, 
including, notably, the sartan drug class.18 Despite this, 
methods to expand the structural diversity of aryl tetrazoles by 
C-H functionalisation are rare, and have tended to involve N-
protected analogues (Scheme 1).19 ?22 Specific to the focus of 
this work, directed and selective C-H functionalisation 
protocols employing unprotected tetrazoles are not known.23 
Accordingly, we sought to address this issue by building on our 
foundations in iridium-catalysed HIE5-7 to deliver a novel 
method of tetrazole C-H functionalization and labelling. 
 We first recognised that existing N-protected tetrazole C-H 
activation protocols20 all involve the use of catalyst systems 
possessing a potential mediator for a concerted metalation-
deprotonation (CMD) pathway, for example a carboxylate or 
carbamate unit.24,25 Secondly, related labelling techniques for 
carboxylic acids require high temperatures and base-mediated 
deuteration methods,10 suggesting only a weakly coordinating 
 
Scheme 1  Directed C-H activation with tetrazoles. 
role for this directing group. These examples of C-H activation 
ĂƌĞ ŵĞĐŚĂŶŝƐƚŝĐĂůůǇ ĚŝƐƚŝŶĐƚ ĨƌŽŵ ƚŚĞ ʍ-complex assisted 
ŵĞƚĂƚŚĞƐŝƐ  ?ʍ-CAM) type processes suggested as being 
operative within iridium-centred HIE catalysis.5,7 Accordingly, 
inspired by the aforementioned studies, and by recent 
carboxylate-directed hydrogenation chemistries,26 ?28 we 
recognised that a modified approach would be required in 
order to deliver unique catalytic activity modes with our 
iridium HIE catalysts and, specifically, to provide a direct 
method of unprotected tetrazole functionalisation. 
 Building on our previous design of experiments (DoE) 
approaches,7,29-31 applicable reaction conditions were 
investigated for labelling unprotected tetrazole 1 with our HIE 
catalysts, 232 and 333 (Table 1). Following their use in 
somewhat related processes,26-28 Et3N and Cs2CO3 were 
selected as bases, and MeOH chosen as the solvent to aid the 
solubility of Cs2CO3. With both bases, ambient temperature 
and short reaction times were insufficient to deliver 
appreciable levels of labelling (Entries 1 ?3). Encouragingly, 
increasing the temperature to 37.5 °C, in combination with the 
use of Cs2CO3 for 2 h, delivered 66% ortho-deuteration of 1 
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Table 1 Reaction discovery and optimisation.a,35 
 
Entry Catalyst Base t / h T / °C %Dc 
1 2 Et3N 1 25 7 
2 2 Cs2CO3 1 25 6 
3 3 Cs2CO3 1 25 10 
4 2 Et3N 2 37.5 10 
5 2 Cs2CO3 2 37.5 15 
6 3 Et3N 2 37.5 0 
7 3 Cs2CO3 2 37.5 66 
8 2 Et3N 3 50 5 
9 2 Cs2CO3 3 50 83 
10 2 Cs2CO3 1 50 72 
11 3 Cs2CO3 1 50 80 
12 3 Cs2CO3 3 50 85 
13d 3 Cs2CO3 3 50 81 
14 3 - 3 50 <5 
a Standard reagent quantities: D2 (1 atm), 1 (0.086 mmol, 13.8 mg), Cs2CO3 (0.043 
mmol, 14.0 mg) or Et3N (0.043 mmol, 0.006 mL), 2 (5 mol%, 4.4 mg) or 3 (5 mol%, 
7.4 mg). b BArF = tetrakis(3,5-bis(trifluoromethyl)phenyl)borate. c D incorporation 
determined by 1H NMR spectroscopy. d 2.5 mol% of catalyst 3 was employed. 
with catalyst 3; this complex also outperformed catalyst 2 with 
either Et3N or Cs2CO3 under similar conditions (Entry 7 versus 
4 ?6). The superiority of Cs2CO3 over Et3N (a CMD versus non-
CMD mediator) as base was drawn out further at 50 °C (Entries 
8 and 9), with the slightly longer reaction time of 3 h (cf. 1 h), 
also providing more optimal deuterium incorporation (Entries 
9 versus 10, and 12 versus 11). In line with our hypothesis, 
base was necessary for effective catalysis (Entry 12 versus 14), 
while lowering the loading of 3 from 5 mol% to 2.5 mol% led to 
only a minor decrease in deuterium incorporation (Entry 13). 
Overall, the conditions detailed in Entry 12 represented a 
promising practicable approach for ortho-deuteration of 
unprotected aryl tetrazoles. 
 Under these selected reaction conditions, the scope of this 
method for C-H activation and labelling of unprotected 2-
aryltetrazoles was investigated (Scheme 2). Satisfactorily, a 
range of electron-donating and -withdrawing substituents 
were tolerated in the para-position (4a ?4d) with good to very 
good levels of deuterium incorporation being recorded. The 
meta-substituted derivatives 4e-f also readily underwent 
labelling. Notably, any preference to label the most accessible 
ortho-site varied depending on the ability of the substituent to 
also further assist labelling at the more hindered position (cf. 
4e and 4f).34 Even sterically restrictive substrates such as 
ortho-methyl derivative 4g could be labelled with high 
efficiency, albeit over a longer reaction time. Benzyltetrazole 
(not shown), however, did not undergo labelling,35 
demonstrating that departure from a 5-membered 
metallacyclic intermediate (5-mmi) is not compatible with 
these optimised conditions. 
 
Scheme 2  Substrate scope of unprotected tetrazole labelling. 
 We next investigated the applicability of our method in 
labelling more structurally challenging and pharmaceutically-
relevant tetrazole structures. To this end, the angiotensin 
receptor blocker, Valsartan 5,36 was subjected to our newly 
developed method, with slightly modified conditions to 
account for the additional acidic site in the molecule (Scheme 
3). Under these conditions, Valsartan 5 was labelled selectively 
in the sole ortho-position, with a high 88% D incorporation and 
only minor degradation of the product (by LC-MS).35 This 
method has also been successfully applied to the 
corresponding tritiation of 5.35 Using 3H NMR spectroscopy 
(Scheme 3, bottom), we confirmed that labelling remained 
selective for the desired position, with the other functional 
groups present not being in a position to direct via a 5-mmi. 
 In a further study, bifunctional substrate 4h was subjected 
to our developed reaction conditions, both with and without 
base (Scheme 4) in order to probe potential site selectivity. 
With base, data from 1H NMR spectroscopy, LC-MS, and HRMS 
shows formation of the di-deuterated product in accordance 
with tetrazole-directed reactivity, such that 4h represents yet 
another viable substrate for this novel labelling method. 
Alternatively, without base, a low conversion was observed, 
along with an almost equal distribution of deuterium in all 
sites of 4h, indicating balanced competition between the 
neutral tetrazole and the nitro directing groups in this case. 
 This developed method not only represents the first 
example of selective ortho C-H functionalisation of 
unprotected tetrazoles, but the requirement for base 
 
Scheme 3  Regioselective isotopic labelling of Valsartan. 
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Scheme 4  Base-dependent control of tetrazole directing ability. 
potentially indicates a new mode of reactivity for catalysts 2 
and 3. Preliminary investigations have thus been initiated in 
order to probe the nature of a base-assisted pathway versus 
the ʍ-CAM-type mechanism previously established for our H/D 
exchange systems.5,7 Firstly, both the optimised reaction 
conditions and the unproductive, base-free counterpart (cf. 
Table 1, Entry 12 versus 14) were applied to substrate 4d, with 
the pH indicator methyl red being added to both reaction 
mixtures after 3 h.37 Without base, a red solution resulted, 
indicating an acidic medium of pH ч 4.4.35 In contrast, and 
perhaps unsurprisingly, the reaction conducted in the 
presence of Cs2CO3 resulted in a yellow solution, indicating a 
more basic medium of pH ш 6.6. Therefore, under the 
operative reaction conditions, the tetrazole substrate (pKa у ? 
in water)38 is most likely deprotonated. This observation was 
consistent with analysis of the 19F NMR spectrum of substrate 
4d, which shows that the tetrazole is deprotonated under the 
basic reaction conditions (Figure 1). This is also in line with that 
observed with substrate 4h (Scheme 4) where a high 
concentration of deprotonated, and more strongly binding, 
tetrazole anion dictates the selectivity of labelling at high pH. 
 A 31P{1H} NMR study of the catalyst in methanol-d4 under 
various conditions revealed an additional role of the base, with 
an intriguing variation in the phosphine-containing species 
present in solution.35 Only when 3, Cs2CO3, and H2 were mixed 
together was the active catalytic species observed.39 
Additional analysis of the NMR spectra of the catalyst35 
suggests that pH may also affect the structure of the active 
catalyst in solution. In addition to these observations, the 
activity of the catalyst was found to depend on the order of 
addition of reactants. Specifically, if the catalyst, tetrazole, 
base and solvent were preheated to 50 °C before the addition 
of D2, no labelling was observed. In contrast, our optimal 
labelling conditions were established by mixing all reaction 
components at room temperature then heating to 50 °C. 
 
Fig. 1 The nature of the substrate and reaction basicity: 19F NMR studies (methanol-
d4). top: 4d only; middle: 4d (1 eq.), 3 (0.05 eq.), Cs2CO3 (0.5 eq.), D2, 27 °C; bottom: 4d 
(1 eq.), 3 (0.05 eq.), D2, no base, 27 °C. 
Table 2 Investigating the effect of the tetrazole electronics. 
 
Entry p-X Substrate %D 
1 H 4a 26 
2 Me 1 14 
3 OMe 4b 10 
4 Cl 4c 73 
5 CF3 4d 67 
Conditions: Tetrazole (0.086 mmol, 1 eq.), 3 (0.0043 mmol, 0.05 eq.), Cs2CO3 
(0.043 mmol, 0.5 eq.), MeOH (1 mL), D2 (1 atm), 50 °C, 5 min. 
 To further enhance the understanding of our developing 
system, we considered suitable kinetic studies. Due to the 
nature of the optimised process, acquisition of rate data was 
impractical. However, halting reactions after 5 min (rather 
than 3 h) offered insight into the relative rates of labelling 
electronically varied tetrazoles (Table 2). Although the rates 
for 4c and 4d (Entries 4 and 5, X = Cl and CF3) were too high, 
even within 5 min, to be considered as initial rates, pseudo-
,ĂŵŵĞƚƚĂŶĂůǇƐŝƐ ĨŽƌyс, ?DĞ ?ĂŶĚKDĞǇŝĞůĚĞĚʌсн ? ? ? ?, 
when assuming the resonance and field effects were almost 
equal.40 It is important to note that the Hammett data alone is 
not sufficient to discount an alternative oxidative addition 
process at iridium, rather than a CMD-type process. However, 
this Hammett analysis is most consistent with a base-assisted 
CMD mechanism, when considering that the non-CMD base, 
Et3N, does not efficiently mediate the C-H activation process. 
Further insight was gained when considering the beneficial 
role of the NHC/phosphine ligand combination and, more 
specifically, when catalyst 2 was compared to derivative 6, 
where the phosphine ligand has been replaced by a more 
labile acetonitrile ligand41 (Table 3). For all unprotected 
tetrazoles (Entries 1 ?5), catalyst 2 proved vastly superior to 6. 
In contrast, the N-Me analogue 4i was labelled to only a small 
extent by both catalysts 2 and 6 (Entry 6). 
 Finally, the source of the deuterium label was probed. 
Employing methanol-d4 as the sole deuterium source with 
tetrazole 1 (under argon rather than D2), a low 8%  
Table 3 Investigating the phosphine/NHC ligand combination. 
 
Entry Substrate X R %D (cat. 2) %D (cat. 6) 
1 4a H H 83 20 
2 1 4-Me H 83 6 
3 4b 4-OMe H 89 11 
4 4c 4-Cl H 78 37 
5 4d 4-CF3 H 93 28 
6 4i H Me 17 (29 b) 22 
a 6 = (COD)Ir(IMes)(MeCN)PF6. b Reaction carried out in the absence of base. 
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Scheme 5  Investigating the effect of the deuterium source. 
D-incorporation was recorded, indicating the necessity for 
molecular D2 (Scheme 5, top). Conversely, employing D2 and 
methanol-d4 together was found to improve the D-
incorporation to 98% (Scheme 5, bottom), compared to 85% 
using MeOH as the solvent (Scheme 2). Consequently, these 
results suggest a non-innocent role of the solvent, interacting 
with the catalyst and D2. 
 In summary, complexes 2 and 3 have been shown to 
effectively catalyse the ortho-deuteration and tritiation of 
pharmaceutically-relevant aryl tetrazoles. Furthermore, this 
method represents the first case of selective C-H 
functionalisation with unprotected tetrazole species. Initial, 
exploratory mechanistic investigations have revealed evidence 
to support a base-assisted CMD-type catalysis process with 
complexes 2 and 3. Future work in this area will concentrate 
on probing further the reaction mechanism(s), and expanding 
the scope of this industrially-aligned C-H activation method to 
encompass related directing functionality. 
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1. General 
1.1 General Experimental Considerations 
 
All reagents were obtained from commercial suppliers (Aldrich, Alfa Aesar, or Strem) 
and used without further purification, unless otherwise stated. Solvents were purchased 
as anhydrous, and stored over molecular sieves (4 Å) under an argon atmosphere. 
 
1H NMR spectra were recorded on Bruker spectrometers, at 300, 400 or 500 MHz. 13C, 
11B, 19F, and 31PNMR spectra were recorded on a Bruker DPX 400 spectrometer at 100 
MHz, 128 MHz, 376 MHz, and 162 MHz, respectively. Chemical shifts are reported in 
ppm. Coupling constants are reported in Hz and refer to 3JH-H couplings, unless 
otherwise stated. 
 
The distribution of hydrogen isotopes in the products was determined by one of two 
liquid chromatography-mass spectrometry (LC-MS) systems: 
 
System 1: using a Symmetry Shield RP18 column, 3.9 mm × 150 mm with gradient 
program. LC column conditions were as follows: 
 
mobile phase A: water (900 mL), acetonitrile (100 mL), TFA (1 mL). 
mobile phase B: water (100 mL), acetonitrile (900 mL), TFA (0.75 mL). 
Flow rate: 0.6 mLmin-1. 
Detection: UV (254 nm and 210 nm). 
 
System 2: using a Dionex Summit LC System with a DAD, coupled to a Thermo MSQ+ 
single quad MS. The LC column used was a Phenomenex Luna C18(2), 3 µm particle 
size, 100 Å pore size, 4.6 mm × 150 mm. 
 
mobile phase A: water (900 mL), acetonitrile (100 mL), formic acid (1 mL). 
mobile phase B: water (100 mL), acetonitrile (900 mL), formic acid (0.75 mL). 
Flow rate: 0.6 mLmin-1. 
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Detection: UV (254 nm and 210 nm). 
 
For system 2, prior to mass detection, eluted LC samples were mixed with a 2.5% (v/v) 
solution of aqueous ammonia in order to form anionic entrants to the MS system. 
 
High resolution mass spectrometry (HRMS) data were acquired in positive or negative 
ESI mode and the method is specifically stated for each compound. Data were obtained 
from the EPSRC UK National Mass Spectrometry Service Centre (NMSSC) at Swansea 
University. Alternatively, HRMS was provided by Sanofi (Frankfurt, Germany) via a 
Bruker micro-TOF-QII in positive ESI mode. Calibration was achieved against a sodium 
formate injection. A Dionex Ultimate 3000 RSLC system was used as an inlet to the MS, 
employing a flow of 0.5 mLmin-1 of 0.044 % TFA in 50% acetonitrile (aq.). Use of this 
system is stated where necessary. 
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1.2 General Procedure ± Deuteration Procedure Using Carousel 
 
All reactions were carried out using a Radley 12-chamber carousel. The water inlet for 
the carousel reflux system was turned on prior to any further reaction set up. To a 25 
mL oven-dried carousel tube was added the requisite tetrazole substrate (0.086 mmol, 
unless otherwise stated), base (0.043 mmol), and iridium(I) precatalyst (0.0043 mmol, 5 
mol%, unless otherwise stated) under air. The requisite solvent (1 mL, unless otherwise 
stated) was added, rinsing the inner walls of the tube. The tube was then sealed at the 
screw cap (with gas inlet tap left open to air) and reconnected to the carousel rack. After 
charging all carousel tubes with their reactants, the air in the tubes was replaced with 
argon before cooling the base of the tubes in the rack to 0 ºC using an ice/water cooling 
bath. Separately, the carousel heating block was set to the desired reaction 
temperature. Whilst in the cooling rack, the cooled flasks were evacuated and flushed 
with deuterium via a balloon, and this cycle repeated one further time. The carousel 
tube gas inlets were then closed, creating a sealed atmosphere of deuterium. After 
sealing the flasks, the rack of tubes was transferred back to the heating block and the 
reaction timer was started. The reaction mixture was stirred for the allotted time before 
removing excess deuterium and replacing with air. At the end of each reaction time, a 2 
µL sample was removed for LC-MS analysis. The reaction solution was then transferred 
to a single-necked flask, using DCM to wash in any residues in the reaction tube, before 
removing the solvent under reduced pressure. The remaining residue was partitioned 
between water (5 mL) and 2-MeTHF (5 mL) in a separating funnel. The organic phase 
was washed with 0.1 M HCl (5 mL), then dried over anhydrous Na2SO4 before filtering 
and concentrating in vacuo. The product was then analysed directly via 1H NMR 
spectroscopy. The integrals were calibrated against a peak corresponding to a position 
not expected to be labelled. 
 
NOTE: it is imperative that the reaction mixture be cooled prior to the introduction of 
deuterium. Heating the basified reaction mixture before adding D2 was found to degrade 
the catalyst before the reaction began.  
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2. Reaction Optimisation for ortho-HIE with N-H Tetrazoles 
 
Table S1 is a reprint of Table 1 of the main text, provided for convenience. The general 
procedure for deuteration using the reaction carousel, as described in Section 1.2, was 
followed. Relevant spectroscopic and spectrometric data are provided in Section 3 
(substrate scope). 
 
Table S1 
Entrya Catalyst Base t / h T / ºC %Db 
1 2 Et3N 1 25 7 
2 2 Cs2CO3 1 25 6 
3 3 Cs2CO3 1 25 10 
4 2 Et3N 2 37.5 10 
5 2 Cs2CO3 2 37.5 15 
6 3 Et3N 2 37.5 0 
7 3 Cs2CO3 2 37.5 66 
8 2 Et3N 3 50 5 
9 2 Cs2CO3 3 50 83 
10 2 Cs2CO3 1 50 72 
11 3 Cs2CO3 1 50 80 
12 3 Cs2CO3 3 50 85 
13c 3 Cs2CO3 3 50 81 
14 3 - 3 50 <5 
a Standard reagent quantities: D2 (1 atm), 1 (0.086 mmol, 13.8 mg), Cs2CO3 (0.043 mmol, 14.0 mg) or 
Et3N (0.043 mmol, 0.006 mL), 2 (5 mol%, 4.4 mg) or 3 (5 mol%, 7.4 mg). 
b D incorporation determined by 1H NMR spectroscopy. 
c Reaction carried out using 2.5 mol% of catalyst 3. 
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3. Substrate Scope for Tetrazole ortho-HIE Protocol 
3.1 Notes 
 
1. In the 1H NMR spectroscopic data reported for the tetrazoles, the N-H protons are not 
visible and are thus not reported. 
 
2. Literature references are provided for the characterisation data of known compounds. 
 
3. For each substrate, an overlay is shown of the 1H NMR spectra of both the starting 
tetrazole (green, top spectrum) and the labelled material (black, bottom spectrum). The 
integrals used to determine the level of incorporation on the labelled material are shown 
on the corresponding spectrum. Please note that only the 1H NMR spectrum of the 
labelled material is aligned with the x-axis (ppm). 
 
4. In all reactions reported for the substrate scope (Scheme 2, main text), catalyst 3 
(7.4 mg, 0.0043 mmol, 5 mol%) was employed. All reactions in Scheme 2 used 1 mL 
from a stock solution of Cs2CO3 (0.043 mM in methanol) as the combined source of 
solvent and base, and all reactions employed a temperature of 50 °C. Following the 
general procedure, results are reported as a) amount of substrate, b) reaction time, and 
c) level of deuterium incorporation. 
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3.2 Tetrazole Substrate Scope 
 
5-Phenyl-1H-tetrazole 4a1 
 
 
 
1H NMR (300 MHz, DMSO-d6)į±8.02 (m, 2H, ArH3), 7.63±7.58 (m, 3H, ArH1 + 
ArH2). IncorporaWLRQ H[SHFWHG DW į ±8.02. Determined against integral at į ±
7.58. 
HRMS (positive ESI): m/z calculated for C7H5D2N4+ [M-d2+H]+: 149.0796; found: 
149.0791. 
 
a) 12.6 mg, 0.086 mmol, b) 3 h and c) 87% D. 
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5-(4¶-Methylphenyl)-1H-tetrazole 12 
 
 
 
1H NMR (300 MHz, DMSO-d6)įG+J = 8.1 Hz, ArH3), 7.40 (d, 2H, J = 8.1 Hz, 
ArH2), 2.38 (s, 3H, ArCH31). ,QFRUSRUDWLRQ H[SHFWHG DW į  Determined against 
integral at į 
HRMS (positive ESI): m/z calculated for C8H7D2N4+ [M-d2+H]+: 163.0947; found: 
163.0946. 
 
a) 13.8 mg, 0.086 mmol, b) 3 h, and c) 85% D. 
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5-(4¶-Methoxyphenyl)-1H-tetrazole 4b3 
 
 
 
1H NMR (300 MHz, DMSO-d6)įG+J = 8.8 Hz, ArH3), 7.15 (d, 2H, J = 8.8 Hz, 
ArH2), 3.83 (s, 3H, OCH31). ,QFRUSRUDWLRQ H[SHFWHG DW į  Determined against 
integral at į 
HRMS (positive ESI): m/z calculated for C8H7D2N4O+ [M-d2+H]+: 179.0896; found: 
179.0895. 
 
a) 15.2 mg, 0.086 mmol, b) 3 h, and c) 86% D. 
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5-(4¶-Chlorophenyl)-1H-tetrazole 4c4 
 
 
 
1H NMR (300 MHz, DMSO-d6)įG+J = 8.6 Hz, ArH2), 7.68 (d, 2H, J = 8.6 Hz, 
ArH1). ,QFRUSRUDWLRQH[SHFWHGDWįDetermined against integral at į 
HRMS (positive ESI): m/z calculated for C7H4D235ClN4+ [M-d2+H]+: 183.0407; found: 
183.0398. 
HRMS (positive ESI): m/z calculated for C7H4D237ClN4+ [M-d2+H]+: 185.0377; found: 
185.0372. 
 
a) 15.5 mg, 0.086 mmol, b) 3 h, and c) 93% D. 
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5-(4¶-Trifluoromethylphenyl)-1H-tetrazole 4d 5 
 
 
 
1H NMR (300 MHz, DMSO-d6)įG+J = 8.3 Hz, ArH2), 7.98 (d, 2H, J = 8.3 Hz, 
ArH1). InFRUSRUDWLRQH[SHFWHGDWįDetermined against integral at į 
HRMS (positive ESI): m/z calculated for C8H4D2F3N4+ [M-d2+H]+: 217.0670; found: 
217.0665. 
 
a) 18.4 mg, 0.086 mmol, b) 3 h, and c) 91% D. 
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5-(3-Methylphenyl)-1H-tetrazole 4e6 
 
 
 
1H NMR (300 MHz, DMSO-d6)įV+$U+5), 7.82 (d, 1H, J = 7.7 Hz, ArH4), 7.48 
(t, 1H, J = 7.7 Hz, ArH3), 7.41±7.39 (m, 1H, ArH2), 2.40 (s, 3H, ArCH3). Incorporation 
H[SHFWHGDWįDQGDetermined against integral at į 
HRMS (positive ESI): m/z calculated for C8H7D2N4+ [M-d2+H]+: 163.0947; found: 
163.0946. 
HRMS (positive ESI): m/z calculated for C8H8DN4+ [M-d1+H]+: 162.0884; found: 
162.0884. 
 
a) 13.8 mg, 0.086 mmol, b) 3 h, and c) 83% D (ArH4), 58% D (ArH5). 
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5-(3-Chlorophenyl)-1H-tetrazole 4f 7 
 
 
 
1H NMR (300 MHz, DMSO-d6) į ±8.06 (m, 1H, ArH4), 8.02±7.98 (m, 1H, ArH3), 
7.68±7.60 (m, 2H, ArH1 + ArH2). Incorporation expected at į±8.06 and 8.02±7.98. 
Determined against integral at į±7.60. 
HRMS (positive ESI): m/z calculated for C7H4D235ClN4+ [M-d2+H]+: 183.0407; found: 
183.0403. 
HRMS (positive ESI): m/z calculated for C7H4D237ClN4+ [M-d2+H]+: 185.0377; found: 
185.0372 
 
a) 15.5 mg, 0.086 mmol, b) 3 h, and c) 91% D (ArH3), 93% D (ArH4). 
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5-(2-Methylphenyl)-1H-tetrazole 4g2 
 
 
 
1H NMR (300 MHz, DMSO-d6) į  G + J = 7.6 Hz, ArH5), 7.50±7.36 (m, 3H, 
ArH2-4), 2.43 (s, 3H, ArCH31). IncoUSRUDWLRQ H[SHFWHG DW į  Determined against 
integral at į 
HRMS (positive ESI): m/z calculated for C8H8DN4+ [M-d1+H]+: 162.0890; found: 
162.0884. 
 
a) 13.8 mg, 0.086 mmol, b) 16 h, and c) 81% D. 
 
 
  
S18 
5-Benzyl-1H-tetrazole1 (Not shown in Scheme 2 but discussed in the manuscript text) 
 
 
 
1H NMR (300 MHz, DMSO-d6) į ±7.25 (m, 5H, ArH1-3), 4.28 (s, 2H, PhCH24). 
IncorporatLRQH[SHFWHGDWį±7.25. Determined against integral at į 
 
a) 13.8 mg, 0.086 mmol, b) 3 h, and c) 0% D. 
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4. Isotope Labelling of Valsartan 
4.1 Deuteration of Valsartan 
 
The deuterium labelling reaction was carried out in a Heidolph Synthesis 1 Liquid 16 
device. NOTE: compared to the Radley carousel, the Heidolph system possesses 
smaller reaction tubes (10 mL versus 25 mL). This results in an overall reduced excess 
of deuterium gas. 
Following the general procedure, no work-up of the sample was carried out. Results 
adjacent to spectroscopic data are reported as: a) amount of 5, b) amount of 3, c) 
amount of Cs2CO3, d) amount of MeOH, e) reaction temperature, f) reaction time, and 
g) %D.  
It has been reported in the literature that Valsartan 5 exists in solution as a pair of 
rotamers, due to hindered rotation around the amide bond.8 In light of these 
complications, full 1H NMR spectroscopic analysis of 5 is not provided. Instead, partial 
analysis of the aromatic and stereogenic protons is given, along with the LC-MS trace 
showing the predominance of 5-d1. 
 
Valsartan 5 
 
 
 
1H NMR (500 MHz, DMSO-d6)į±7.64 (m, 2H, ArH1 + ArH3), 7.56±7.52 (m, 2H, 
ArH2 + ArH4), 7.25±7.02 (2 × d, with each d split in the ratio 2:1 according to the 
presence of two rotamers, 4H in total, both d share J = 8.3 Hz, ArH5 + ArH6), 4.59 and 
4.15 (1 × d split in the ratio 2:1 according to the presence of two rotamers, 1H in total, 
S20 
both d share J = 10.6 Hz, CH12). ,QFRUSRUDWLRQ H[SHFWHGDW į ±7.64. Determined 
against integral at į±7.02. 
HRMS (positive ESI): m/z calculated for C24H29DN5O3+ [M-d1+H]+: 437.2412; found: 
437.2406. 
 
a) 18.5 mg, 0.043 mmol, b) 3.7 mg, 0.002 mmol, 5 mol%, c) 14.0 mg, 0.043 mmol, d) 
1mL, e) 50 °C, f) 6 h, and g) 88% D. 
 
The 1H NMR spectrum of deuterium labelled Valsartan 5 is shown below, followed by 
expansions of the 7.4±7.9 ppm and 4.1±4.6 ppm regions, respectively. From this, it can 
be seen that the stereogenic proton, H12, remains largely unchanged, with an estimated 
total integration of ~1H: 
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LC-MS (System 1) supports the presence of 5-d1 as the major product: 
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4.2 Tritiation of Valsartan 
 
The tritiation of Valsartan 5 was carried out at Sanofi (Frankfurt) using a standard 
Tritec® tritium manifold. Valsartan 5 (3.5 mg, 8.0 µmol), Cs2CO3 (2.62 mg, 8.0 µmol, 1 
eq.), and catalyst 3 (0.7 mg, 8.0 µmol, 6.7 mol%) were dissolved in MeOH (0.7 mL) in a 
1.0 mL reaction flask before being connected to the manifold. The solution was frozen in 
liquid nitrogen and the flask was evacuated, then charged with tritium (1.5 Ci, 212±370 
mbar). The reaction mixture was then allowed to warm to room temperature over 15 min 
before stirring at r.t. for a further 30 min (212 mbar pressure). The reaction mixture was 
then heated to 50 °C (370 mbar pressure) and stirred for 45 min before cooling again to 
r.t. and stirring for a final 2 h. Purification and isolation via HPLC gave the tritiated 
product (0.91 mg, 5-T1, 98.9% radiochemical purity). Radiochemical purity was 
established by comparison of the activity of the product-containing CH3CN/H2O fraction 
following HPLC purification (1168.7 MBq), with the activity of 5-T1 (15 Ci/mmol), which 
was measured by TOF-MS.  
 
3H NMR (533 MHz, DMSO-d6)į 7.63 (d, 1H, 3JH-T = 9.1 Hz, ArH1) 
HRMS (positive ESI): m/z calculated for C24H29TN5O3+ [M-t1+H]+: 438.2431; found: 
438.2502. 
 
The 3H NMR spectrum, below, shows tritium incorporation ortho to the tetrazole only: 
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5. Investigating Nitro versus Tetrazole Labelling 
 
In both studies, substrate 4h (16.4 mg, 0.086 mmol) was employed with catalyst 3 (7.4 
mg, 0.0043 mmol, 5 mol%). The basic reaction (Table S2, entry 1) employed base from 
a stock solution of Cs2CO3 (1 mL, 0.043 mM in MeOH) as the combined source of 
solvent and base. The base-free reaction (Table S2, entry 2) used MeOH (1 mL) as the 
solvent rather than the stock base solution. The general labelling procedure for the 
optimized deuteration conditions was followed otherwise, and no work-up was used 
before analysis. The results are summarised in Table S2. 
 
Table S2 
 
 
 
Entry Conditions %Da %Db 
1a basic 89 8 
2b base-free 30 27 
a Conditions: 4h (16.4 mg,), Cs2CO3 (1 mL, 0.043 mM in MeOH), 3 (5 mol%), 3 h, 50 °C. 
b Conditions: 4h (16.4 mg), MeOH (1 mL), 3 (5 mol%), 3 h, 50 °C. 
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5-(4-Nitrophenyl)-1H-tetrazole 4h9 
 
 
 
1H NMR (300 MHz, DMSO-d6)įG+J = 8.8 Hz, ArH1), 8.29 (d, 2H, J = 8.8 Hz, 
ArH2). Incorporation expected at all positions. For the base-free reaction, incorporation 
at positions ArH1 and ArH2 was measured against an equimolar quantity of the following 
internal standard (15.5 mg, 0.086 mmol): 
 
 
 
1H NMR (300 MHz, DMSO-d6)įV+$U+3), 3.67 (s, 3H, ArOCH31), 2.23 (s, 6H, 
ArCH326LJQDODWįXVHGWRFDOLEUDWHthe extent of integrals in labelled 4i. 
 
For the base-mediated reaction, the ratio of 1H NMR spectrum signals in the product 
was compared to HRMS data in order to estimate the %D adjacent to each directing 
group. Specifically, a 1H NMR spectrum residual peak ratio of 1:0.095 b:a (i.e. favouring 
tetrazole labelling) was compared to HRMS peaks [M-dn+H]+ (n = 1, 2, 3) in the ratio 
7.4:85.0:7.6 (d1:d2:d3). This translates to approximately 89% Da and 8% Db. 
 
HRMS (positive ESI): m/z calculated for C7H4D2N5O2+ [M-d2+H]+: 194.0647; found: 
194.0655. 
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With base: 
 
 
Without base: 
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6. Mechanistic Studies 
6.1 Investigating the pH of the Reaction and Likely State of the 
Tetrazole 
 
Methyl red indicator test 
 
As described in the results section (main text), substrate 4d was used in repeat 
experiments of the conditions from Table 1, Entries 12 and 14. In the first instance, 
these two reactions were compared visually (after the 3 h reaction time) without the 
addition of indicator (top, Figure S1). Separately, two more reactions were carried out, 
and a similar visual comparison made after the addition of a spatula-tip of methyl red 
into each carousel flask (bottom, Figure S1). See Figure S1 below for a comparison of 
the reactions with and without indicator; left flask ± without base; and right flask ± with 
base. 
 
 
 
Figure S1. The nature of the substrate versus reaction basicity. 
  
Without methyl red 
With methyl red 
No base 
No base 
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19F NMR studies of substrate 4d 
 
NOTE: all NMR studies in this section were carried out separately from the methyl red 
experiments. The following NMR data relates to the right-hand side of Figure 1 in the 
main text. 
 
The relevant data for substrate 4d in methanol-d4 are provided below: 
 
 
 
1H NMR (400 MHz, Methanol-d4)įG+J = 8.6 Hz, ArH2), 7.89 (d, 2H, J = 8.6 
Hz, ArH1). 
19F NMR (376 MHz, Methanol-d4)įí64.6 (CF3). 
 
To assess the effects of the basic reaction conditions on tetrazole 4d, the substrate 
(18.4 mg, 0.086 mmol), catalyst 3 (7.4 mg, 0.0043 mmol), and Cs2CO3 (14.0 mg, 0.043 
mg) were dissolved in methanol-d4 (1 mL) and added to an oven-dried NMR tube. After 
sealing the tube with a rubber septum, D2 was bubbled through the tube for 30 min prior 
to NMR spectroscopic analysis at 300 K. 
 
Similarly, for assessing the base-free conditions, a sample identical to that above, 
minus the addition of Cs2CO3, was prepared in a separate NMR tube. 
 
Comparative 1H NMR spectrum resonances (not shown in the main text) are provided 
below. In addition, all peak positions and relevant integrations are listed in Table S3, 
below the spectra. 
  
S30 
 
 
 
Table S3 
Entry Conditions 19F NMR / ppm 1H NMR / ppma 
Integral ratio 
(ArH2:ArH1) 
1 Tetrazole only -64.6 8.24, 7.89 2.0 : 2.0 
2b Basic reaction -64.2 8.24, 7.77 0.3 : 2.0 
3 Base-free reaction -64.6 8.26, 7.91 1.8: 2.0  
a Position of each resonance stated only (no coupling given). 
b Significant deuterium labelling observed in ortho-positions. 
 
Tetrazole only 
Basic reaction 
Base-free reaction 
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6.2 31P NMR Spectroscopic Study of the Catalyst with Various 
Components of the Tetrazole Labelling Method 
 
The relevant spectroscopic analyses of complex 3 in methanol-d4 are given below. 
NOTE: the complex is only sparingly soluble in methanol-d4 and has to be shaken 
vigorously to obtain a red solution. 
 
K4±Cycloocta-1,5-diene(1,3-dimesitylimidazol-2-ylidene)(triphenylphosphine)iridium(I) 
tetrakis[(3,5-trifluoromethylphenyl)]borate 310 
 
 
 
1H NMR (400 MHz, methanol-d4) į  V + 1&+ &+1 ±7.59 (m, 12H, 
ArHBArF), 7.52±7.48 (m, 3H, ArH), 7.38±7.33 (m, 6H, ArH), 7.24±7.19 (m, 6H, ArH), 7.13 
(s, 2H, ArH), 6.76 (s, 2H, ArH), 4.48±4.45 (m, 2H, COD CH), 3.39±3.36 (m, 2H, COD 
CH), 2.37 (s, 6H, ArCH3), 2.17 (s, 6H, ArCH3), 1.83 (s, 6H, ArCH3), 1.76±1.52 (m, 6H, 
COD CH2), 1.34±1.29 (m, 2H, COD CH2). 
31P NMR (162 MHz, methanol-d4)į33K3). 
19F NMR (376 MHz, methanol-d4)įí64.3 (BArF ArCF3). These spectral details were 
largely unchanged between 300 K and 318 K. 
 
Triphenylphosphine 
31P NMR (162 MHz, methanol-d4)įí5.94 (PPh3). 
 
Triphenylphosphine oxide 
31P NMR (162 MHz, methanol-d4)į3K3P=O). 
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A 31P{1H} NMR spectroscopic study of the catalyst in methanol-d4 under various 
conditions revealed an intriguing variation in the phosphine-containing species present 
in solution. A single peak at 16.2 ppm was visible for the precatalyst, 3, in the absence 
of any other reagent. Interestingly, whether mixing either 3 with H2, or 3 with Cs2CO3, 
complete conversion to a peak at 32.3 ppm, corresponding to Ph3P=O, was observed in 
both cases. Only when 3, Cs2CO3, and H2 were mixed together, were distinct peaks at 
14.2 and 13.3 ppm observed, corresponding to the active catalyst, with both signals 
persisting in the presence of tetrazole 4d. Figure S2 below shows the 31P{1H} NMR 
spectroscopic study of complex 3 with various components of the tetrazole labelling 
method. The specific details of each entry (1 ± 7) are detailed following the image. 
 
 
 
Figure S2. 31P{1H} NMR study of complex 3.  
7. Ph3P 
6. Ph3P=O 
3. Catalyst + H2 
2. Catalyst + Cs2CO3 
 
1. Precatalyst 
Active species? 
5. Catalyst + H2 + base + 4d 
4. Catalyst + H2 + Cs2CO3 
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Analysis of Catalyst 3 + Cs2CO3 
 
Catalyst 3 (7.4 mg, 0.0043 mmol) and Cs2CO3 (2.8 mg, 0.0086 mmol, 2.0 eq.) were 
dissolved in methanol-d4 (1 mL) in an NMR tube, which was then sealed under an argon 
atmosphere. The contents of the tube were shaken vigorously for 10 min, causing a red 
to yellow colour change. NMR spectroscopic analysis of the sample at 300 K is provided 
(primarily 31P). Additional spectral overlays are provided for 1H NMR spectroscopic data 
(relative to catalyst 3) where formal peak assignment is not yet possible. 
 
31P NMR (162 MHz, methanol-d4)įXQNQRZQ 
19F NMR (376 MHz, methanol-d4)įí64.3 (BArF ArCF3). 
1H NMR (400 MHz, methanol-d4): overlayed with 3 (green) below (7.8±6.3 ppm, 6.2±
2.4 ppm and 2.4±1.0 ppm regions, respectively). 
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Similar results were obtained with only 1 eq. of Cs2CO3 (14.0 mg, 0.043 mmol) under 
otherwise identical conditions. 
  
S35 
Analysis of Catalyst 3 + H2 
 
Catalyst 3 (7.4 mg, 0.0043 mmol) was placed in methanol-d4 (1 mL) in an NMR tube, 
which was then sealed using a rubber septum. Hydrogen gas was bubbled through the 
mixture with shaking, dissolving the precatalyst and giving a clear yellow solution. 
 
31P NMR (162 MHz, methanol-d4)įXQNQRZQ 
19F NMR (376 MHz, methanol-d4)įí64.3 (BArF ArCF3). 
1H NMR (400 MHz, methanol-d4): overlayed with 3 (green). 
 
 
 
1R K\GULGH VLJQDOV į  SSPZHUH REVHUYHG This is presumably due to exchange 
with methanol-d4. 
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Analysis of Catalyst 3 + H2 + Cs2CO3 
 
Catalyst 3 (7.4 mg, 0.0043 mmol) and Cs2CO3 (14.0 mg, 0.043 mmol) were dissolved in 
methanol-d4 (1 mL) in an NMR tube, which was then sealed using a rubber septum. 
Hydrogen gas was then bubbled through the mixture, producing a clear yellow solution. 
 
31P NMR (162 MHz, methanol-d4)įXQNQRZQ 
19F NMR (376 MHz, methanol-d4)įí64.3 (BArF ArCF3). 
1H NMR (400 MHz, methanol-d4): The overlap provided shows the current experiment 
(black) versus the previous experiment (green), where catalyst 3 was mixed only with 
H2. Analysis of the aliphatic region shows the formation of at least two distinct patterns 
of mesityl substitution. Analysis of the hydride region shows a trace doublet (í9.7 ppm) 
with a suspected 3JH-P = 13.6 Hz, consistent with a cis-ligated phosphine relative to at 
least one hydride ligand. 
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Analysis of Catalyst 3 + H2 + Cs2CO3 + tetrazole 4d 
 
Catalyst 3 (7.4 mg, 0.0043 mmol), Cs2CO3 (14.0 mg, 0.043 mmol) and tetrazole 4d (1.1 
mg, 0.0086 mmol) were dissolved in methanol-d4 (1 mL) in an NMR tube, which was 
then sealed using a rubber septum. Hydrogen gas was bubbled through the mixture, 
producing a clear yellow solution. 
 
31P NMR (162 MHz, methanol-d4)įWUDFHXQNQRZQ 
19F NMR (376 MHz, methanol-d4)į-64.3 (BArF ArCF3), -64.2 (tetrazole CF3). 
1H NMR (400 MHz, methanol-d4): The overlay provided shows the current experiment 
(black) versus the previous experiment (red), where the tetrazole was absent. Firstly, it 
appears that similar species are formed in solution in the presence or absence of 
tetrazole 4d. Most interestingly, however, complete exchange of the ortho-protons was 
observed, despite the fact that H2 has been used in place of D2. The use of a 1:2 
mixture of 3:4d does not allow definitive conclusions to be drawn regarding the catalytic 
reactions. Nonetheless, this may indicate a favorable exchange between H (in the H2) 
and D (in methanol-d4), mediated by iridium. Analysis of the hydride region allowed 
observation of the same trace doublet (í9.7 ppm) with a suspected 3JH-P = 12.8 Hz, 
consistent with a cis-ligated phosphine relative to at least one hydride. 
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6.3 Investigating the Effect of Substrate Electronics in Ir-catalysed 
Tetrazole Labelling 
 
Following the general labelling procedure, tetrazoles 1 and 4a±4d were subjected to the 
optimised labelling conditions as reported above for the reaction scope. The only 
change was in the reaction time (now 5 min rather than 3 h). For brevity, readers are 
directed to the spectroscopic data and reagent stoichiometries reported in Section 3.2. 
For construction of the Hammett plot, the %D values for substrates manifesting <30% D 
incorporation after 5 min (X = H, Me, and OMe) were used as reaction rate surrogates. 
These values are shown below, in Table S4. 
 
Table S4 
a Not considered in the Hammet analysis. 
b Field (F) and resonance (R) values obtained from the literature.11 
c ıP = a.F + b.R such that  ıP produces a straight line of R2 = 1 when plotted against log10(%DX/H). Here, a 
= 1.00 and b = 0.98. In other words, field and resonance effects are almost balanced. 
  
Entry X Substrate %D %DX/%DH log10(%DX/H) Fb Rb ıPc 
1 H 4a 26 1.00 0.00 0.00 0.00 0.00 
2 Me 1 14 0.54 í0.27 0.01 í0.18 í0.17 
3 OMe 4b 10 0.38 í0.41 0.29 í0.56 í0.26 
4a Cl  4c  73 2.81 - - -  
5a CF3 4d 67 2.58     
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The graph in Figure S3 shows the U value calculated from Table S4: 
 
 
Figure S3. Pseudo-Hammett values for 1, 4a and 4b. 
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6.4 Investigating the Role of the PPh3 Ligand in Ir-catalyzed Tetrazole 
Labelling  
 
Synthesis of K4±cycloocta-1,5-diene(1,3-dimesitylimidazol-2-
ylidene)(acetonitrile)iridium(I) hexafluorophosphate 6 
 
The yellow complex [(COD)Ir(IMes)Cl] (0.250 g, 0.389 mmol, 1 eq.),12 was dissolved in 
dry THF (10 mL) in a flame-dried round-bottom flask, fitted with a stopcock sidearm. 
After all the solids had dissolved, AgPF6 (0.098 g, 0.389 mmol, 1 eq.) was added, 
affording a yellow to opaque orange colour change and formation of a precipitate. The 
reaction mixture was stirred for 15 min at r.t. before filtration through Celite under argon. 
Addition of dry acetonitrile (0.020 mL, 0.016 g, 0.389 mmol, 1 eq.) to the clear orange 
solution resulted in the immediate appearance of a bright red colour. After stirring for 16 
h at r.t., the THF solution was reduced to a quarter of its original volume and the residue 
triturated using cold hexane, to afford the product as an orange solid (0.241 g, 78% 
yield). 
 
 
 
Appearance: orange/yellow solid. 
m.p.: >175 °C (dec.). 
FTIR (neat): 2980, 2935, 2920, 2885, 1607, 1495, 1335, 1240 cm-1. 
1H NMR (400 MHz, CDCl3)įV+1&+ &+1 (bs, 4H, ArH), 4.03±4.01 
(m, 2H, COD CH), 3.46±3.44 (m, 2H, COD CH), 2.48 (s, 3H, CH3CN), 2.41 (s, 6H, 
ArCH3), 2.18 (s, 12H, ArCH3), 1.89±1.82 (m, 2H, COD CH2), 1.75±1.66 (m, 2H, COD 
CH2), 1.61±1.51 (m, 4H, COD CH2). 
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13C NMR (100 MHz, CDCl3)į140.0, 135.0, 134.9, 129.3, 125.1, 124.2, 82.7, 
65.8, 32.8, 29.0, 21.1, 18.3, 3.44. 
13C JMOD NMR (100 MHz, CDCl3): į 140.0 (CH3CN, inverted), 135.0 (inverted), 134.9 
(inverted), 129.3, 125.1 (inverted), 124.2, 82.7 (inverted), 65.8 (inverted), 32.8 
(inverted), 29.0 (inverted), 21.1, 18.3, 3.44 (CH3CN, inverted).  
31P NMR (162 MHz, CDCl3)įí144.4 (septet, 1JP-F = 711.8 Hz, PF6). 
19F NMR (376 MHz, CDCl3)įí73.2 (d, 1JP-F = 711.8 Hz, PF6). 
HRMS (positive ESI): No mass ion was observed nor was expected, based on 
literature precedent.13 Suspected fragment (structure shown below) m/z calculated for 
[M ± PF6 ± COD ± MeCN ± 2H]+: 495.1412; found: 495.1402. 
 
 
Application of NHC/Acetonitrile Catalyst 6 in Tetrazole Labelling 
 
Following the general procedure (page S5), tetrazoles 1, 4a ± 4d, and 4i were subjected 
to identical labelling conditions as reported earlier for the reaction scope. The only 
change was in the catalyst (2 and 6, rather than 3). The comparison of catalysts here 
was chosen in order to maintain the same counterion whilst comparing the 
phosphine/NHC and acetonitrile/NHC combinations. For brevity, readers are directed to 
the spectroscopic data and reagent stoichiometries reported in Section 3.2. The data 
for catalysts 2 versus 6 are shown in Table S5 below. Spectroscopic data for substrate 
4i are also provided. 
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Table S5 
 
 
Entry Substrate X R %D (catalyst 2)a %D (catalyst 6)b 
1 4a H H 83 20 
2 1 Me H 83 6 
3 4b OMe H 89 11 
4 4c Cl H 78 37 
5 4d CF3 H 93 28 
6 4i H Me 17 (29)c 22 
 
a Conditions: Substrate (0.086 mmol), Cs2CO3 (1 mL from 0.043 mM solution in MeOH), 2 (4.3 mg, 0.0043 
mmol, 5 mol%). 
b Conditions: Substrate (0.086 mmol), Cs2CO3 (1 mL from 0.043 mM solution in MeOH), 6 (3.4 mg, 0.0043 
mmol, 5 mol%). 
c The reaction in parenthesis was carried out in the absence of base. 
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5-Phenyl-N-methyltetrazole 4i14 
 
 
 
1H NMR (300 MHz, Methanol-d4)į±7.82 (m, 2H, ArH3), 7.68±7.61 (m, 3H, ArH1-
2), 4.21 (s, 3H, NCH34). ,QFRUSRUDWLRQ H[SHFWHG DW į ±7.82. Determined against 
integral at į 
13.8 mg, 0.086 mmol of substrate 4i were employed. 
 
Entry 6, catalyst 2: 
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Entry 6, catalyst 2 (parenthesis): 
 
 
 
Entry 6, catalyst 6: 
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6.5 Investigating the Importance of N-H Tetrazoles and Changes in the 
Active Catalyst ± Additional Reactions Not in the Main Text 
 
In reaction both with and without base, substrate 4i (13.8 mg, 0.086 mmol) was 
employed with catalyst 3 (7.4 mg, 0.0043 mmol, 5 mol%). The base-free reaction (A, 
below) used MeOH (1 mL) as the solvent rather than the stock base solution. The basic 
reaction (B, below) employed base from a stock solution of Cs2CO3 (1 mL, 0.043 mM in 
MeOH) as the combined source of solvent and base. The general labelling procedure 
for the optimised deuteration conditions was followed otherwise, and no work-up was 
used before analysis. As for similar reactions employing catalyst 2 (Table S5), the N-
protected tetrazole gave only low levels of deuterium incorporation under the reaction 
conditions (Table S6, below), showing again that the method is selective for 
unprotected tetrazoles. 
 
 
 
Table S6 
Entry Conditions % D 
1a basic 28 
2b base-free 17 
a Conditions: 4i (13.8 mg, 0.086 mmol), Cs2CO3 (1 mL, 0.043 mM in MeOH), 
3 (5 mol%). 
b Conditions: 4i (13.8 mg, 0.086 mmol), MeOH (1 mL), 3 (5 mol%). 
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6.6 Probing the Deuterium Source in Ir-catalysed Tetrazole Labelling 
 
Labelling of Substrate 1 in Methanol-d4 in the Absence of D2 
 
Following the general labelling procedure, tetrazole 1 (13.8 mg, 0.086 mmol), Cs2CO3 
(14.0 mg, 0.043 mmol), and catalyst 3 (7.4 mg, 0.0043 mmol) were dissolved in 
methanol-d4 (1 mL) and added to an oven-dried carousel tube under an argon 
atmosphere. Here, no cooling was carried out as no D2 was introduced to the system. 
The reaction tube was heated to 50 °C (as before) and the solution stirred for 3 h. The 
solvent was removed in vacuo and the product analysed directly via 1H NMR 
spectroscopy (8% D incorporation). See Section 3.2 for the spectroscopic data relating 
to 1. 
 
Labelling of Substrate 1 in Methanol-d4 in the Presence of D2 
 
Following the general labelling procedure, tetrazole 1 was subjected to identical 
labelling conditions as reported in Section 3.2 for the reaction scope, but replacing 
MeOH with methanol-d4. The concentrated reaction mixture was analysed directly via 
1H NMR spectroscopy (98% D incorporation). See Section 3.2 for the spectroscopic 
data relating to 1. 
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7. Additional HRMS Data 
 
Tetrazole 1 
 
HRMS (positive ESI; NMSSC): 
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Tetrazole 4a 
 
HRMS (positive ESI; Sanofi): 
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Tetrazole 4b 
 
HRMS (positive ESI; NMSSC): 
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Tetrazole 4c 
 
HRMS (positive ESI; Sanofi): 
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Tetrazole 4d 
 
HRMS (positive ESI; Sanofi): 
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Tetrazole 4e 
 
HRMS (positive ESI; NMSSC): 
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Tetrazole 4f 
 
HRMS (positive ESI; Sanofi): 
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Tetrazole 4g 
 
HRMS (positive ESI; Sanofi): 
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Tetrazole 4i (base-mediated) 
 
HRMS (positive ESI; Sanofi): 
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Tritiated Valsartan 5-t 
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8. Additional LC-MS Data 
 
Tetrazole 4a 
 
LC-MS(System 2): 
 
 
 
 
Tetrazole 4b 
 
LC-MS(System 2): 
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Tetrazole 4c 
 
LC-MS(System 2): 
 
 
 
 
Tetrazole 4d 
 
LC-MS(System 2): 
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Tetrazole 4e 
 
LC-MS(System 2): 
 
 
 
 
 
Tetrazole 4f 
 
LC-MS(System 2): 
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Tetrazole 4g 
 
LC-MS(System 2): 
 
 
 
 
 
5-Benzyl-1H-tetrazole 
 
LC-MS(System 2): 
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